Foresight Diagnostics

The ALPHA3 Trial: Next-Gen CAR T and MRD Testing in LBCL If successful, ALPHA3 could redefine when and for whom CAR T is delivered, changing treatment paradigms and bringing us closer to curing more patients in the frontline setting.

Check out this article from Inside Precision Medicine, where
Allogene's CMO Zach Roberts discusses the use of minimal residual disease (MRD) testing in the ALPHA3 trial. Read the article here: bit.ly/44WoscL #Precisionmedicine #oncology

A few days ago, Foresight had our annual holiday party, where we celebrated our incredible team. Their dedication, innovation, and collaboration has driven breakthroughs in #PrecisionOncology and strengthened our mission to improve patient outcomes.

Wishing everyone a safe and happy 2026!

Foresight presents Real-World Data on ultrasensitive #MRD surveillance in B-cell lymphoma today at #ASH2025 (10:45–11:00am ET). The presentation will be posted to the “Resources” section of the website following the session: foresight-dx.com/resources/

Foresight Diagnostics is now part of Natera Genetics, uniting Natera’s best-in-class precision diagnostics portfolio and commercial and operational infrastructure with our innovative phased-variant ctDNA-MRD technology and lymphoma leadership.

Read more: foresight-dx.com/press_releas...

#ASH25 kicks off in a few days! More than 10 presentations feature #ForesightCLARITY MRD analysis—thanks to our biopharma and academic partners. Don’t miss our oral on CLARITY in #DLBCL surveillance: Sun, Dec 7, 10:45–11am ET. Release: bit.ly/48MWGBP + visit booth #2165!

The Foresight team is excited to be at #ASH2025! Catch our Oral Presentation on #ForesightCLARITY in #DLBCL surveillance on Sun., Dec. 7 from 10:45–11:00am ET.

Stop by booth #2165 to meet our executive team and clinical experts or reach out to BD@foresight-dx.com to connect.

Join Dr. David Kurtz of Foresight Diagnostics as he reviews Allogene’s phase 2 ALPHA3 trial of cema-cel, an allogeneic CAR T in MRD+ LBCL after frontline therapy, and CLARITY™ MRD data, trial updates, and milestones. Add to calendar: calendarlink.com/event/wpYmu

Inside Foresight’s Mission to Redefine Cancer Monitoring | Discover how Foresight Diagnostics is pushing MRD detection to new limits with its ultrasensitive technology that has the potential to unlock new actionable insights.

Foresight is pushing the boundaries of cancer diagnostics. Co-founders Jake Chabon and Max Diehn and Fierce Biotech’s Chris Hayden discuss how #MRD testing is transforming care and our ultrasensitive approach focused on clinically-actionable decisions for patients: bit.ly/49sQOib

We’re honored to be recognized as one of DeloitteUS’s 2025 Fast 500 companies! As we continue advancing cancer drug development and patient care through innovative diagnostics combining precision genomics and cutting-edge science, we’re inspired to keep pushing boundaries.

Last night, our team attended the Colorado Avalanche’s Hockey Fights Cancer game with UCHealth - a powerful night of honoring cancer warriors and supporting those affected by cancer. Proceeds benefited the American Cancer Society.

#ForesightCLARITY #Oncology

YouTube video by Fierce Life Sciences Foresight Diagnostics executive sees MRD testing as future of cancer care

Foresight is pushing the boundaries of cancer diagnostics. CBO John Truesdell and Fierce Biotech's Chris Hayden discuss how our ultrasensitive #MRD approach can enable clinically-actionable decisions in oncology: youtu.be/OihBGDqEN2s

#ctdna #mrd

Will we see you at #ASH25? Foresight will present the first real-world study of ctDNA dynamics in treated #LBCL, showcasing how #ultrasensitive MRD detection can guide personalized treatment. Excited to connect on the next stage of MRD-driven care: bit.ly/47kdmQE

Spirits are high in the office this week with a little Halloween fun! Our team came together for some friendly competition during our costume contest, sharing laughs and creativity, along with some impressive outfits. Thanks to everyone who joined in!

Welcome Carrina Cappadona to the team! As our new VP of Patient and Client Experience, Carinna will lead efforts to ensure that patients, clinicians, and providers are supported as we work to develop innovative diagnostic tests to advance cancer drug development and patient care.

Our Foresight CLARITY™ MRD platform detects the presence of #MRD from circulating tumor DNA (ctDNA) with sensitivity to multiple cancers.

Learn about how Foresight CLARITY™ is shaping the next-gen of cancer monitoring: bit.ly/4mpDDRW

#UltrasensitiveScience

Excited to attend #ESMO2025 in Berlin!

Foresight team members will be onsite connecting with experts on the latest breakthroughs in #oncology. Curious about our #MRD detection technology, #ForesightCLARITY? Let’s connect!

Reach out here: bit.ly/4mZE7yK

#BeyondClarity #UltrasensitiveScience

Episode 65. Circulating Tumor DNA in DLBCL with Dr. Ash Alizadeh and Dr. David Russler-Germain Podcast Episode · Blood Cancer Talks · 09/24/2025 · 53m

Curious how ctDNA could reshape care for aggressive cancers like #DLBCL? Hear from co-founder Ash Alizadeh on Blood Cancer Talks on its transformative potential, from advances in detection to breakthrough clinical data. Listen here: bit.ly/4mBkyfr

Excited to join #FierceBiotechWeek! Our CBO John Truesdell and Allogene Therapeutics CMO Zachary Roberts will discuss how next-gen #MRD is reshaping oncology, driving personalized care, advancing therapies, and informing decisions to improve outcomes. Register here: bit.ly/4nk0C1A

The Foresight team was proud to support Blood Cancer United at our local #LightTheNight Walk! We sponsored the walkway and cheered on patients, survivors, families, and supporters. It was an inspiring night honoring those impacted by blood cancers and funding life-saving research.

We had a great time at World CB & CDx Summit this week! A highlight was hosting a lunch & learn with QIAGEN, where we explored opportunities for MRD-driven companion diagnostic development and distribution.

Connect with our BD team to learn more about us: bit.ly/4mZE7yK

We’re thrilled to welcome McKenzie Carlisle, PhD, to the Foresight team! As our new Senior Director of Regulatory Operations and Compliance, she’ll lead regulatory strategy for our IVD pipeline, helping drive innovative diagnostics to advance oncology drug development and patient care.

On #WorldCancerResearchDay, we reaffirm our goal to give patients actionable data when it matters most. With Foresight CLARITY™, powered by our PhasED-Seq™ technology, we aim to uncover residual disease at key points in treatment. Learn more about us: bit.ly/4pwH3EY

The Foresight team is excited to join Blood Cancer United's #LightTheNight walk in Denver on Sept. 25 to honor and support those impacted by #bloodcancer. Walk with us, or find an event near you to help raise funds for life-saving research. Sign up here: bit.ly/3IjzEYS

Looking forward to the Liquid Biopsy Symposium! Michiel Pegtel, PhD and HOVON will present on the value of Foresight CLARITY™ #MRD at end of #DLBCL therapy in a real-world cohort and founder Max Diehn, MD, PhD, will present on advances in liquid biopsies: bit.ly/4mSKNPL

Excited to be at the upcoming World CB & CDx Summit! Meet us to learn about our technology for detecting #MRD with unmatched sensitivity in cancer types. Ask about our QIAGEN partnership to develop CDx kits for #lymphoma and our global CDx capabilities. More details: world-cdx.com

Reflecting on a successful #WCLC25! Our team shared our work with University Health Network Toronto on advancing ctDNA analysis in #NSCLC with Foresight CLARITY™ and connected with colleagues, collaborators and others dedicated to improving outcomes in #lungcancer. More details: bit.ly/4gmQh2t

On #WLAD we recognize challenges patients face post-treatment: ~30% of #DLBCL patients relapse, often taking 1–2 years to confirm with current methods. Foresight CLARITY™ seeks to detect relapse sooner, enabling precise care. Learn more: bit.ly/45yFqgO #BloodCancerMonth

Next-Gen MRD Testing: Foresight’s Leap in Sensitivity with Jake Chabon and Dave Kurtz Catching a cancer relapse before any scan could see it is the ultimate goal for minimal residual disease or MRD testing.

How is research shaping the future of cancer care? Hear from our CEO & CMO on Mendelspod on Foresight’s origin story, our next-gen #MRD testing with unmatched sensitivity, detecting relapse earlier, and what’s next for cancer care. Listen here: bit.ly/46pUm1A
#Oncology

Company Announcement: Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin’s Lymphoma. The Agreement Closes the Litigation Between the Parties. More information: bit.ly/46fSoki

#MRD #Oncology

Our team is at #WCLC25 this weekend! We’re sharing data with University Health Network Toronto on ctDNA analysis from the ctDNA-Lung-DETECT study in #NSCLC using Foresight CLARITY™, our ultrasensitive next-gen assay, showing high #MRD detection. Details: bit.ly/4g9ynQN